International Journal of Obesity最新文献

{"title":"Socioeconomic differences in the cost-effectiveness of a telephone-based intervention for obesity prevention in early childhood.","authors":"Thomas Lung, Alison Hayes, Li Ming Wen, Huilan Xu, Vicki Brown, Louise A Baur, Philayrath Phongsavan, Anagha Killedar","doi":"10.1038/s41366-025-01904-4","DOIUrl":"https://doi.org/10.1038/s41366-025-01904-4","url":null,"abstract":"<p><strong>Objectives: </strong>This study investigated the cost-effectiveness of an early childhood obesity prevention intervention providing telephone and short message service (SMS) support to mothers of children aged 2-4 years by socioeconomic position (SEP).</p><p><strong>Methods: </strong>A model-based SEP-specific economic evaluation of the intervention was conducted. SEP-specific intervention costs and effects at age 5 years were derived from the trial data and applied to a cohort of 4- to 5-year-old Australian children. We used the validated EQ-EPOCH microsimulation model to predict SEP-specific body mass index (BMI) trajectories, quality-adjusted life years (QALYs) and health care costs until 17 years of age. Incremental cost-effectiveness ratios (ICERs) and acceptability curves were derived for each SEP group, using 2023 Australian dollars (AUD).</p><p><strong>Results: </strong>From an Australian health payer perspective, the ICERs for the low-SEP group were $131 per BMI unit avoided and $6549 per QALY gained, compared to the high-SEP group at $1161 per BMI unit avoided and $41,462 per QALY gained. Results were robust to sensitivity analyses varying the intervention effect size, intervention costs, healthcare costs, discount rate and disutility from overweight. The probability that the intervention was cost-effective at a willingness-to-pay threshold of $50,000 per QALY gained was extremely high in the low-SEP group (99.7%) and marginally cost-effective in the high-SEP group (49.6%).</p><p><strong>Conclusions: </strong>A telephone and SMS intervention was more cost-effective in low-SEP groups compared with high-SEP groups. Prioritizing families from socioeconomically disadvantaged backgrounds for this intervention will reduce healthy weight inequalities in childhood.</p>","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real world efficacy of naltrexone/bupropion for weight management in obesity and after bariatric surgery.","authors":"Marie Yskout, Nele Steenackers, Jarne Hoste, Sofia Pazmino, Caroline Simoens, Nele Mattelaer, Ellen Deleus, Matthias Lannoo, Ann Mertens, Bart Van der Schueren, Roman Vangoitsenhoven","doi":"10.1038/s41366-025-01870-x","DOIUrl":"https://doi.org/10.1038/s41366-025-01870-x","url":null,"abstract":"<p><strong>Background: </strong>Insufficient weight loss or weight regain after metabolic and bariatric surgery (MBS) is frequent, and evidence to support the use of pharmacotherapy for weight management is limited.</p><p><strong>Methods: </strong>In this single-centre retrospective cohort study, the effectiveness of naltrexone/bupropion (NB) for weight control in surgery-naive and post-MBS patients was evaluated. Data was collected between 2016 and 2022 on all patients started on NB after multidisciplinary consult. Patients received weekly dose escalation up to 32/360 mg daily per the manufacturer's protocol, with submaximal doses administered in cases of adverse effects or sufficient therapeutic response. Weight evolution, metabolic status, adherence and adverse events were analysed at 4 and 12 months after NB initiation. Data are presented as median (interquartile range).</p><p><strong>Results: </strong>A total of 151 patients were included, 111 were surgery-naive and 40 with prior MBS. The median time after MBS was 7.1 years (4.2, 14.9). Among the post-MBS patients, 18 (45%) patients had undergone Roux-en-Y gastric bypass and 11 (27.5%) sleeve gastrectomy. Four months after initiation of NB, 46.8% of the surgery-naive patients and 67.5% of the post-MBS patients continued using NB, with a median weight loss of 6.4% (3.0, 10.1) and 6.3% (2.3, 12.1) respectively. At 12-months, 38.5% of surgery-naive patients and 63.0% of post-MBS patients had continued NB, with median weight loss of 8.8% (5.0, 16.7) and 10.0% (4.5, 16.5) respectively. There was no statistically significant difference in weight loss between the surgery-naive and post-MBS group. Weight loss was not significantly influenced by whether the maximal dose was reached in both the surgery-naive patients (p = 0.38) and the post-MBS patients (p = 0.72).</p><p><strong>Conclusion: </strong>Real-world data show that NB treatment is equally effective in surgery-naive patients and in patients experiencing weight regain after bariatric surgery, regardless of the maximal dose administered.</p>","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts from the 10th meeting of the Association for the Study of Obesity: UK Congress on Obesity 2025.","authors":"","doi":"10.1038/s41366-025-01880-9","DOIUrl":"10.1038/s41366-025-01880-9","url":null,"abstract":"","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":"1-45"},"PeriodicalIF":3.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacotherapy and metabolic/bariatric surgery: either or both?","authors":"Nick Finer","doi":"10.1038/s41366-025-01897-0","DOIUrl":"https://doi.org/10.1038/s41366-025-01897-0","url":null,"abstract":"","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of vagus nerve stimulation on metabolism: a systematic review and meta-analysis.","authors":"Tianxiao Shen, Xinyue Tang, Yixin Pan, Hua He, Kejia Hu","doi":"10.1038/s41366-025-01871-w","DOIUrl":"https://doi.org/10.1038/s41366-025-01871-w","url":null,"abstract":"<p><strong>Background: </strong>Vagus Nerve Stimulation (VNS) has long been a standard surgical procedure for patients with treatment-resistant depression or epilepsy. However, several studies have confirmed a side-effect of VNS treatment as weight loss. Animal model studies (e.g., rats, minipigs) and clinical trials have shown promising outcomes regarding weight and appetite, but further statistical analysis is limited.</p><p><strong>Methods: </strong>We searched PubMed and several databases for rat model studies, minipig model studies, and human trials between 1966 and March 2024. All reported changes in weight, appetite, and energy expenditure were assessed. Meta-analysis was employed to calculate the overall pooled effects across studies with different durations or measurements.</p><p><strong>Results: </strong>Of the 529 papers identified, 15 studies were eligible for this meta-analysis, including 12 animal trials and 4 human randomized controlled trials (RCTs). VNS showed a significant effect on reducing weight gain in both animal models (rats 95% CI -0.91 to -0.27, I² = 88%, Z = 3.60, P = 0.0003; minipigs 95% CI -209.17 to -36.61, I² = 98%, Z = 2.79, P = 0.005) and human trials (95% CI 1.06 to 2.07, I² = 98%, Z = 6.11, P < 0.00001). VNS also significantly reduced appetite (95% CI -6.47 to -5.82, I² = 95%, Z = 36.91, P < 0.00001) and changed energy expenditure (95% CI -2.83 to -0.81, I² = 80%, Z = 3.53, P = 0.0004) in the rat model. The effect on human energy expenditure could not be estimated.</p><p><strong>Conclusion: </strong>VNS has demonstrated notable impacts on reducing weight, suppressing appetite, and enhancing energy expenditure in rat and minipig models, indicating a promising therapeutic application in addressing metabolic disorders. Human trials also showed the effectiveness and safety of VNS on metabolism.</p>","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of fetal FTO gene variants with maternal postload glucose levels in pregnancy.","authors":"Gábor Firneisz, Ákos Nádasdi, Botond A Nemes, László Németh, Klara Rosta, Jürgen Harreiter, Alexandra Kautzky-Willer, Anikó Somogyi, Zoltán Benyó","doi":"10.1038/s41366-025-01896-1","DOIUrl":"https://doi.org/10.1038/s41366-025-01896-1","url":null,"abstract":"<p><strong>Objective: </strong>The FTO rs9939609 variant is a major common genetic risk factor of adult obesity. We hypothesized that the rs9939609 variant of the fetus alters the plasma glucose (PG) levels during oral glucose tolerance test (OGTT) routinely performed between the 24-28th gestational week.</p><p><strong>Methods: </strong>We analysed the data of mother-neonate pairs from our prior gestational diabetes mellitus (GDM) case-control study (Hungarian-Austrian set, n = 858) and the HAPO study European ancestry subset (HAPO-EUR, n = 1374) using pre-pregnancy body mass index (BMI) and maternal age as covariates. The rs8050136 (complete LD with rs9939609) was used in the HAPO-EUR data set.</p><p><strong>Results: </strong>Fetal FTO variants were associated (dominant genetic model) with decreased maternal 60'min PG values (ß_{Hungarian-Austrian} = -1.39 mmol/L, p = 1.97*10^-4; ß_HAPO-EUR = -0.18 mmol/L, p = 4.36*10^-2; ß_combined = -0.33 mmol/L, p = 2.11*10^-4) and with reduced incremental area under glucose curve at OGTT (ß_{Hungarian-Austrian} =-1.70 mmol*h/L, p = 3.83*10^-4; ß_HAPO-EUR = -0.23 mmol*h/L, p = 2.91*10^-2; ß_combined = -0.39 mmol*h/L, p = 1.61*10^-4).</p><p><strong>Conclusion: </strong>FTO risk variants carried by the fetus may indirectly influence maternal metabolism and could be associated with a flatter OGTT curve driven by the reduced 1 h postload PG levels in pregnancy.</p>","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal side effects of incretin-based obesity management medications: insights from healthcare professionals and patients' experiences.","authors":"Rotem Refaeli, Gizel Green, Mona Boaz, Idit Dotan, Asnat Raziel, Tamar Peffer-Gik, Assaf Buch, Shiri Sherf-Dagan","doi":"10.1038/s41366-025-01887-2","DOIUrl":"https://doi.org/10.1038/s41366-025-01887-2","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal (GI) symptoms are the most frequently reported adverse events of incretin-based Obesity Management Medications (OMMs). There is a lack of comprehensive knowledge and experience regarding the management of GI side effects in patients treated with incretin-based OMMs, highlighting the need to develop practical recommendations. This study aims to gain an in-depth understanding of the perceptions and experiences of patients and healthcare professionals (HCPs) regarding the GI side effects associated with incretin-based OMMs treatment, focusing on the unique perspectives of these two populations.</p><p><strong>Methods: </strong>A qualitative descriptive research design, including two focus group sessions with seven HCPs (physicians and dietitians) and semi-structured interviews with eight patients who are treated with incretin-based OMMs, was performed. The interviews were analyzed using qualitative content analysis.</p><p><strong>Results: </strong>Two major themes emerged from the study. The first theme revolves around the different characteristics of GI side effects, encompassing four sub-themes: (1) types of common GI side effects; (2) the timing of GI side effect occurrence; (3) challenges in diagnosis; and (4) their impact on quality of life and treatment continuity. The second theme focuses on strategies for the prevention and management of GI side effects during treatment with incretin-based OMMs encompassing five sub-themes: (1) preliminary education; (2) tailored dose escalation; (3) dietary and lifestyle modifications for the treatment of specific GI symptoms; (4) medical therapy aimed to alleviate symptoms; and (5) multidisciplinary follow-up.</p><p><strong>Conclusion: </strong>Newly identified characteristics of GI side effects have emerged, enabling a more comprehensive understanding of the phenomenon. Moreover, HCPs proposed detailed strategies for preventing and managing GI side effects. The insights gained could be beneficial for both HCPs and patients aiming to improve the quality of care and medication adherence.</p>","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of fluoxetine on body weight, waist circumference, and body mass index in individuals who are overweight or have obesity: a meta-analysis of randomized controlled trials.","authors":"Fan Cui, Fanchao Dong, Zhiqiang Yang, Mohammad Safargar, Mihnea-Alexandru Găman, Hamed Kord-Varkaneh, Jianjun Dong","doi":"10.1038/s41366-025-01891-6","DOIUrl":"https://doi.org/10.1038/s41366-025-01891-6","url":null,"abstract":"<p><p>The effect of fluoxetine administration on body weight (BW), waist circumference (WC), and body mass index (BMI) remains inconclusive, as many studies have reported contradicting results. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess the impact of fluoxetine prescription on these anthropometric indices. A comprehensive systematic review was conducted in PubMed/MEDLINE, SCOPUS, Web of Science, and EMBASE for manuscripts indexed before Jun 28st, 2025. The results were computed using the DerSimonian and Laird random effects model and reported as weighted mean differences (WMD) with 95% confidence intervals (CI). The current meta-analysis included 22 RCT arms (2348 individuals: placebo = 1166; fluoxetine = 1182) on BW, 2 RCT arms (77 individuals: placebo = 39; fluoxetine = 38) on WC, and 4 RCT arms (215 individuals: placebo = 105; fluoxetine = 110) on BMI. The present meta-analysis included 22 RCT arms (2348 individuals: placebo = 1166; fluoxetine = 1182) on BW. Fluoxetine treatment significantly reduced BW (WMD: -2.095 kg, p < 0.001), with significant heterogeneity noted among the RCTs (I² = 84.7%, P < 0.001). Fluoxetine supplementation decreased BW more substantially when the dose was ≥60 mg/day (WMD: -2.759 kg, p < 0.001) compared to <60 mg/day (WMD: -1.017 kg, p = 0.001), in trials lasting ≤12 weeks (WMD: -3.000 kg, p < 0.001) versus >12 weeks (WMD: -1.114 kg, p = 0.047), and when administered to individuals living with obesity (WMD: -2.246 kg, p < 0.001) compared to those living with overweight (WMD: -1.972 kg, p < 0.001). Fluoxetine did not impact WC or BMI values. Fluoxetine administration is associated with a reduction in BW, particularly when prescribed at doses ≥60 mg/day, during short-term interventions (≤3 months), and in individuals living with obesity.</p>","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between plasma sphingosine-1-phosphate, plasma apolipoprotein M, obesity, and the risk of incident type 2 diabetes: a prospective cohort study.","authors":"Kang-Chih Fan, I-Weng Yen, Chia-Hung Lin, Chung-Yi Yang, Chun-Heng Kuo, Szu-Chi Chen, Ya-Pin Lyu, Hsien-Chia Juan, Mao-Shin Lin, Shu-Huei Wang, Hung-Yuan Li","doi":"10.1038/s41366-025-01890-7","DOIUrl":"https://doi.org/10.1038/s41366-025-01890-7","url":null,"abstract":"<p><strong>Objectives: </strong>Type 2 diabetes (T2D) is a growing global health challenge, necessitating novel biomarkers for early risk assessment. This study investigates the associations between plasma sphingosine-1-phosphate (S1P), apolipoprotein M (ApoM), obesity measures, and the risk of incident T2D.</p><p><strong>Methods: </strong>We utilized data from the Taiwan Lifestyle Study, a prospective cohort initiated in 2006. A total of 1207 individuals without diabetes at baseline were included. Abdominal fat distribution was assessed using computed tomography, while plasma S1P and ApoM levels were measured using ELISA.</p><p><strong>Results: </strong>During an average follow-up of 5.93 years, 152 participants developed diabetes. Plasma S1P correlated with visceral, peritoneal, and retroperitoneal fat (all p < 0.001), while ApoM correlated with total, subcutaneous, and visceral fat (all p < 0.001). In adjusted models, plasma S1P significantly predicted diabetes (HR 0.52, 95% CI 0.35-0.77, p = 0.001), whereas plasma ApoM did not (HR 1.16, 95% CI 0.94-1.43, p = 0.170). The predictive model incorporating S1P showed an AUC of 0.7698 and a concordance statistic of 0.7637, outperforming traditional risk factors.</p><p><strong>Conclusions: </strong>Plasma S1P and ApoM are both associated with obesity. However, only plasma S1P is a good predictive biomarker for incident T2D, underscoring its potential for early risk assessment and intervention.</p>","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential associations of subcutaneous and visceral fat with bone turnover markers: A study on bariatric surgery patients with severe obesity and individuals without obesity.","authors":"Prince Dadson, Eleni Rebelos, Maria K Jaakkola, Milena Monfort-Pires, Ronja Ojala, Henri Honka, Kari K Kalliokoski, Riku Klén, Pirjo Nuutila, Kaisa K Ivaska","doi":"10.1038/s41366-025-01888-1","DOIUrl":"https://doi.org/10.1038/s41366-025-01888-1","url":null,"abstract":"<p><strong>Background: </strong>Obesity suppresses bone turnover markers (BTMs) in circulation, and weight loss after metabolic and bariatric surgery (MBS) increases BTM levels. However, the relationship between regional fat distribution and BTMs has not been thoroughly investigated. This study aimed to determine which specific fat compartments - namely abdominal and femoral subcutaneous fat (SF), intraperitoneal fat, extraperitoneal fat, and total visceral fat (VF) - have the greatest impact on circulating BTM levels following weight loss induced by MBS.</p><p><strong>Methods: </strong>The study comprised a cohort of individuals with severe obesity (n = 46) studied before and 6 months after MBS, either sleeve gastrectomy (SG, n = 25) or Roux-en-Y gastric bypass (RYGB, n = 21). Healthy individuals without obesity (n = 25) served as controls. Regional fat depots were quantified with magnetic resonance imaging. The BTMs included Tartrate-Resistant Acid Phosphatase 5b, C-terminal Telopeptide of Type I Collagen (CTX), Procollagen Type I N-terminal Propeptide (PINP), and Total (TotalOC), Carboxylated (cOC), and Undercarboxylated (ucOC) osteocalcin.</p><p><strong>Results: </strong>In the pooled baseline analysis, no significant associations were observed between fat depots and BTMs (all p > 0.05). Postoperatively, distinct patterns emerged between surgical groups. In the SG cohort, femoral SF was inversely associated with cOC levels (p < 0.05) compared to the RYGB group. Following RYGB, extraperitoneal, intraperitoneal, and total VF were significantly associated with TotalOC, while intraperitoneal and total VF were also negatively associated with ucOC (all p < 0.05) compared to SG. All p-values were adjusted for false discovery rate to correct for multiple comparisons.</p><p><strong>Conclusions: </strong>The findings suggest a specific interaction between intraperitoneal, extraperitoneal, and total visceral compartments and bone metabolism following RYGB. These observed relationships highlight the need for clinicians to consider regional fat distribution when assessing bone health in post-MBS patients.</p><p><strong>Clinicaltrials: </strong></p><p><strong>Gov registration numbers: </strong>NCT00793143 and NCT01373892.</p>","PeriodicalId":14183,"journal":{"name":"International Journal of Obesity","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}